

Co-enrolment list HIT-HARD Trial

This is a non-exhaustive list of trials for which co-enrolment with the HIT-HARD trial is allowed. For studies not mentioned on this page, we are always able to evaluate the possibility of co-enrolment. Please take contact with the HIT-HARD study team to propose any other trials for co-enrolment.

Trial	Lead centre – PI	Approved?
BALANCE – Impact of antimicrobial treatment strategies on emergence of resistance	UZ Gent Prof. Dr. Liesbet De Bus	Co-enrolment is approved
CrusAders – Creep and Maintenance fluid Sodium Chloride Administration reduction in critically ill adults	UZ Antwerpen Prof. Dr. Niels Van Regenmortel	Co-enrolment is approved
PREVENT	Radboudumc Prof. Tim Frenzel	Co-enrolment is approved
HEAL Sepsis - a systems immunology approach for nanomedicine to heal sepsis and its long-term complications	Radboudumc Prof. Dr. M.G. Netea	Co-enrolment is approved
CTIN816B12202 : A Multicenter, randomized, double-blind, placebo-controlled, four-arm, parallel-group, dose-finding phase 2b study to investigate the safety and efficacy of TIN816 via a single intravenous infusion in the treatment of participants with sepsis-associated acute kidney injury (SA-AKI) Novartis. 2024-	Novartis Daniel Monney	Co-enrolment is approved
EPO-TRAUMA - ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients	Australian and New Zealand Intensive Care Research Centre Vicki Papanikolaou	Co-enrolment is approved

PRECISE-2 - PRotEin provision in Critical IllneSs -2	Ziekenhuis Oost-Limburg Dieter Mesotten	Co-enrolment is approved
EASY BOOST - An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospital Stay Following On-Pump Coronary Artery Bypass Grafting Surgery	EBI Anti Sepsis B.V. Prof. Dr. Peter Pickkers Radboudumc	Co-enrolment is approved